---
title: "Luye Pharma Converts $25 Million of Tranche A Bonds"
description: "Luye Pharma Group Ltd. has converted US$25 million of its Tranche A Bonds at a conversion price of HK$3.672 per share. This is part of a broader financial strategy involving US$100 million in converti"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256525986.md"
published_at: "2025-09-09T09:37:47.000Z"
---

# Luye Pharma Converts $25 Million of Tranche A Bonds

> Luye Pharma Group Ltd. has converted US$25 million of its Tranche A Bonds at a conversion price of HK$3.672 per share. This is part of a broader financial strategy involving US$100 million in convertible bonds due in 2025, potentially affecting its financial structure and investor relations. The latest analyst rating for Luye Pharma (HK:2186) is a Buy, with a price target of HK$5.00. Luye Pharma focuses on innovative pharmaceutical products, primarily in the Chinese market, and has a current market cap of HK$14.49 billion.

Luye Pharma Group ( (HK:2186) ) has shared an update.

Luye Pharma Group Ltd. announced the conversion of US$25,000,000 of its Tranche A Bonds at a conversion price of HK$3.672 per share. This move is part of the company’s ongoing financial strategy involving US$100,000,000 5.85% convertible bonds due in 2025, which may impact its financial structure and investor relations.

The most recent analyst rating on (HK:2186) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.

**More about Luye Pharma Group**

Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, primarily engaged in the development, production, and sale of innovative pharmaceutical products. The company focuses on the global market, with a particular emphasis on the Chinese market.

**Average Trading Volume:** 106,358,790

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$14.49B

### Related Stocks

- [02186.HK - LUYE PHARMA](https://longbridge.com/en/quote/02186.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 綠葉製藥任命夏蓮加入提名委員會 | 綠葉製藥集團有限公司已任命獨立非執行董事夏蓮女士為其提名委員會成員，任命自 2025 年 12 月 31 日起生效。該委員會現包括主席羅玉林教授、張華橋先生、蔡思聰先生以及夏蓮女士 | [Link](https://longbridge.com/en/news/271205840.md) |
| 綠葉製藥授予恩華製藥在中國獨家銷售三種長效抗精神病藥物的權利 | 綠葉製藥集團有限公司已授予江蘇南華和信藥業有限公司在中國獨家商業化三種長效注射抗精神病藥物的權利。該協議包括十年的期限和一次性不可退還的許可費 2000 萬美元。綠葉製藥保留產品所有權、市場授權和知識產權，並將負責生產和供應 | [Link](https://longbridge.com/en/news/270707579.md) |
| SoFi 與 OSL 集團 (863) 達戰略合作，引入數字資產交易服務，業務首次擴張至美國本土以外市場 | SoFi Securities（香港）有限公司與 OSL 集團達成戰略合作，首次將數字資產交易服務擴展至美國以外市場。此合作為香港投資者提供通過 SoFi Hong Kong 應用程式交易多種數字資產的機會，標誌著 SoFi 全球業務的重要 | [Link](https://longbridge.com/en/news/275689746.md) |
| 伊朗總統：準備好接受對於自身核計畫的「任何查核」 | （法新社德黑蘭 11 日電）伊朗總統裴澤斯基安（Masoud Pezeshkian）今天表示，伊朗已準備好接受對於自身核計劃的「任何查核」，並強調德黑蘭方面並不尋求發展核武。裴澤斯基安在伊朗伊斯蘭革命 47 週年紀念活動中表示：「我們並不尋 | [Link](https://longbridge.com/en/news/275665209.md) |
| 踏雪遊學長白山！與付鵬等金融大咖研討 2026 資產配置風向 | 2026 年 3 月 4 日至 6 日，華爾街見聞將舉辦長白山論壇，邀請知名經濟學家付鵬等金融大咖探討 2026 年全球市場走勢與資產配置。論壇將討論即將發生的關鍵事件，包括全國兩會和美聯儲議息會議。活動吸引了近 20 位高淨值人士參與，名 | [Link](https://longbridge.com/en/news/275732493.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.